Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution - NEC
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:IART
- CUSIP: 45798520
- Web: www.integralife.com
Capitalization:- Market Cap: $4.16 billion
- Outstanding Shares: 75,620,000
Average Prices:- 50 Day Moving Avg: $53.45
- 200 Day Moving Avg: $46.43
- 52 Week Range: $37.71 - $56.42
P/E:- Trailing P/E Ratio: 65.52
- Foreward P/E Ratio: 24.79
- P/E Growth: 2.49
Sales & Book Value:- Annual Revenue: $1.01 billion
- Price / Sales: 4.12
- Book Value: $11.33 per share
- Price / Book: 4.86
Profitability:- EBIDTA: $235.27 million
- Net Margins: 6.66%
- Return on Equity: 16.67%
- Return on Assets: 7.36%
Debt:- Debt-to-Equity Ratio: 1.00%
- Current Ratio: 3.02%
- Quick Ratio: 1.75%
Misc:- Average Volume: 528,567 shs.
- Beta: 0.75
- Short Ratio: 10.23
Frequently Asked Questions for Integra LifeSciences Holdings Corporation (NASDAQ:IART)
What is Integra LifeSciences Holdings Corporation's stock symbol?
Integra LifeSciences Holdings Corporation trades on the NASDAQ under the ticker symbol "IART."
When did Integra LifeSciences Holdings Corporation's stock split? How did Integra LifeSciences Holdings Corporation's stock split work?
Integra LifeSciences Holdings Corporation's stock split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly created shares were issued to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of Integra LifeSciences Holdings Corporation stock prior to the split would have 200 shares after the split.
How were Integra LifeSciences Holdings Corporation's earnings last quarter?
Integra LifeSciences Holdings Corporation (NASDAQ:IART) posted its quarterly earnings data on Wednesday, April, 26th. The company reported $0.39 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.40 by $0.01. The business earned $258.60 million during the quarter, compared to analysts' expectations of $254.19 million. Integra LifeSciences Holdings Corporation had a return on equity of 16.67% and a net margin of 6.66%. The business's quarterly revenue was up 9.2% compared to the same quarter last year. During the same period last year, the business posted $0.38 EPS. View Integra LifeSciences Holdings Corporation's Earnings History.
What guidance has Integra LifeSciences Holdings Corporation issued on next quarter's earnings?
Integra LifeSciences Holdings Corporation issued an update on its FY17 earnings guidance on Wednesday, April, 26th. The company provided EPS guidance of $1.88-1.94 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.91. The company issued revenue guidance of $1.12-1.14 billion, compared to the consensus revenue estimate of $1.13 billion.
Where is Integra LifeSciences Holdings Corporation's stock going? Where will Integra LifeSciences Holdings Corporation's stock price be in 2017?
9 brokerages have issued 1 year price targets for Integra LifeSciences Holdings Corporation's shares. Their forecasts range from $42.00 to $65.00. On average, they expect Integra LifeSciences Holdings Corporation's stock price to reach $52.06 in the next twelve months. View Analyst Ratings for Integra LifeSciences Holdings Corporation.
Who are some of Integra LifeSciences Holdings Corporation's key competitors?
Some companies that are related to Integra LifeSciences Holdings Corporation include Steris Plc (STE), Bio-Rad Laboratories (BIO), West Pharmaceutical Services (WST), DexCom (DXCM), Hill-Rom Holdings (HRC), VWR Corporation (VWR), NuVasive (NUVA), ICU Medical (ICUI), LivaNova PLC (LIVN), Neogen Corporation (NEOG), Nevro Corp. (NVRO), Haemonetics Corporation (HAE), Inogen (INGN), Halyard Health (HYH), MiMedx Group (MDXG), CONMED Corporation (CNMD), Asante Solutions (PUMP) and K2M Group Holdings (KTWO).
Who are Integra LifeSciences Holdings Corporation's key executives?
Integra LifeSciences Holdings Corporation's management team includes the folowing people:
- Stuart M. Essig Ph.D., Independent Chairman of the Board
- Peter J. Arduini, President, Chief Executive Officer, Director
- Glenn G. Coleman, Chief Financial Officer, Principal Accounting Officer, Corporate Vice President
- Lisa Evoli, Corporate Vice President, Chief Human Resources Officer
- Kenneth Burhop Ph.D., Chief Scientific Officer, Corporate Vice President
- John Mooradian, Corporate Vice President - Global Operations and Supply Chain
- Richard D. Gorelick, Corporate Vice President, General Counsel, Administration, Secretary
- Robert T. Davis Jr., Corporate Vice President, President — Specialty Surgical Solutions
- Judith E. O'Grady R.N., Corporate Vice President - Global Regulatory Affairs
- Daniel L. Reuvers, Corporate Vice President, President - Specialty Surgical Solutions
Who owns Integra LifeSciences Holdings Corporation stock?
Integra LifeSciences Holdings Corporation's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (1.34%), Vaughan Nelson Investment Management L.P. (1.19%), First National Bank of Omaha (0.04%), Nisa Investment Advisors LLC (0.03%), Louisiana State Employees Retirement System (0.03%) and US Bancorp DE (0.03%). Company insiders that own Integra LifeSciences Holdings Corporation stock include Christian S Schade, Daniel L Reuvers, Glenn Coleman, James M Sullivan, Joseph Vinhais, Peter J Arduini, Raymond G Murphy, Richard D Gorelick and Stuart Essig. View Institutional Ownership Trends for Integra LifeSciences Holdings Corporation.
Who sold Integra LifeSciences Holdings Corporation stock? Who is selling Integra LifeSciences Holdings Corporation stock?
Integra LifeSciences Holdings Corporation's stock was sold by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C., Fisher Asset Management LLC, Independent Portfolio Consultants Inc., First National Bank of Omaha, Capstone Asset Management Co., Dubuque Bank & Trust Co. and Diversified Trust Co. Company insiders that have sold Integra LifeSciences Holdings Corporation stock in the last year include Glenn Coleman, James M Sullivan, Peter J Arduini, Raymond G Murphy, Richard D Gorelick and Stuart Essig. View Insider Buying and Selling for Integra LifeSciences Holdings Corporation.
Who bought Integra LifeSciences Holdings Corporation stock? Who is buying Integra LifeSciences Holdings Corporation stock?
Integra LifeSciences Holdings Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Vaughan Nelson Investment Management L.P., Mitsubishi UFJ Asset Management UK Ltd., V Wealth Management LLC, State of Alaska Department of Revenue, Cutler Group LP, Aperio Group LLC, Nisa Investment Advisors LLC and US Bancorp DE. View Insider Buying and Selling for Integra LifeSciences Holdings Corporation.
How do I buy Integra LifeSciences Holdings Corporation stock?
Shares of Integra LifeSciences Holdings Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Integra LifeSciences Holdings Corporation's stock price today?
One share of Integra LifeSciences Holdings Corporation stock can currently be purchased for approximately $55.04.
MarketBeat Community Rating for Integra LifeSciences Holdings Corporation (NASDAQ IART)MarketBeat's community ratings are surveys of what our community members think about Integra LifeSciences Holdings Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Integra LifeSciences Holdings Corporation (NASDAQ:IART) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 7 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.78) |
| Consensus Price Target: | $52.06 (5.42% downside) |
Analysts' Ratings History for Integra LifeSciences Holdings Corporation (NASDAQ:IART)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/10/2017 | Cantor Fitzgerald | Reiterated Rating | Overweight | $65.00 | Low |  |
| 6/24/2017 | Oppenheimer Holdings, Inc. | Set Price Target | Buy | $60.00 | Low | |
| 5/31/2017 | Jefferies Group LLC | Boost Price Target | Buy | $52.00 -> $58.00 | Low | |
| 5/2/2017 | Royal Bank Of Canada | Reiterated Rating | Sector Perform -> Sector Perform | $46.00 -> $48.00 | Low | |
| 3/22/2017 | Piper Jaffray Companies | Reiterated Rating | Overweight | $47.00 | Low | |
| 1/13/2017 | Barclays PLC | Reiterated Rating | Equal Weight | $84.00 -> $42.00 | N/A | |
| 1/6/2017 | JMP Securities | Upgrade | Market Perform -> Outperform | $50.00 | N/A | |
| 10/28/2016 | Lake Street Capital | Upgrade | Hold -> Buy | $46.00 | N/A | |
| 9/23/2016 | Argus | Boost Price Target | Buy | $45.00 -> $52.50 | N/A | |
| 7/13/2016 | J P Morgan Chase & Co | Initiated Coverage | Overweight | | N/A | |
| 11/12/2015 | Citigroup Inc. | Initiated Coverage | Buy | $37.50 | N/A | |
| 9/21/2015 | Bank of America Corporation | Upgrade | Neutral -> Buy | $36.00 -> $39.50 | N/A | |
| 7/29/2015 | Raymond James Financial, Inc. | Upgrade | Market Perform -> Outperform | | N/A | |
(Data available from 7/23/2015 forward)
Earnings History for Integra LifeSciences Holdings Corporation (NASDAQ:IART)Earnings History by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ IART)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 4/26/2017 | Q1 17 | $0.40 | $0.39 | $254.19 million | $258.60 million | View | N/A | |
| 2/23/2017 | Q4 2016 | $0.52 | $0.52 | $257.27 million | $255.70 million | View | N/A | |
| 10/27/2016 | Q3 | $0.89 | $0.93 | $249.30 million | $250.30 million | View | Listen | |
| 7/28/2016 | Q216 | $0.76 | $0.79 | $243.17 million | $249.30 million | View | Listen | |
| 4/27/2016 | Q116 | $0.73 | $0.74 | $230.66 million | $236.80 million | View | Listen | |
| 2/25/2016 | Q4 | $0.86 | $0.87 | $241.11 million | $241.20 million | View | Listen | |
| 11/3/2015 | Q315 | $0.74 | $0.75 | $224.08 million | $226.40 million | View | Listen | |
| 7/30/2015 | Q215 | $0.73 | $0.79 | $239.91 million | $244.10 million | View | Listen | |
| 4/30/2015 | Q115 | $0.63 | $0.76 | $229.69 million | $233.70 million | View | N/A | |
| 2/24/2015 | Q414 | $0.89 | $0.94 | $244.39 million | $252.20 million | View | Listen | |
| 11/3/2014 | Q314 | $0.74 | $0.76 | $233.50 million | $229.70 million | View | Listen | |
| 8/5/2014 | Q214 | $0.63 | $0.68 | $229.32 million | $231.40 million | View | N/A | |
| 5/1/2014 | Q114 | $0.58 | $0.57 | $213.30 million | $215.00 million | View | N/A | |
| 2/25/2014 | Q413 | $0.81 | $0.78 | $223.37 million | $220.80 million | View | N/A | |
| 10/28/2013 | Q313 | $0.70 | $0.72 | $214.05 million | $213.20 million | View | N/A | |
| 8/1/2013 | Q2 2013 | $0.55 | $0.60 | $207.30 million | $205.50 million | View | N/A | |
| 5/2/2013 | Q1 2013 | $0.37 | $0.39 | $195.20 million | $196.70 million | View | N/A | |
| 2/21/2013 | Q4 2012 | $0.76 | $0.78 | $215.90 million | $214.40 million | View | N/A | |
| 10/24/2012 | | $0.77 | $0.85 | | | View | N/A | |
| 7/26/2012 | | $0.69 | $0.74 | | | View | N/A | |
| 4/25/2012 | | $0.60 | $0.71 | | | View | N/A | |
| 2/23/2012 | | $0.55 | $0.72 | | | View | N/A | |
| 10/31/2011 | | $0.77 | $0.77 | | | View | N/A | |
| 7/28/2011 | | $0.61 | $0.70 | | | View | N/A | |
| 4/28/2011 | | $0.66 | $0.66 | | | View | N/A | |
| 2/24/2011 | | $0.73 | $0.80 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Integra LifeSciences Holdings Corporation (NASDAQ:IART)2017 EPS Consensus Estimate: $1.92
2018 EPS Consensus Estimate: $2.26
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 4 | $0.38 | $0.48 | $0.42 |
| Q2 2017 | 4 | $0.43 | $0.47 | $0.45 |
| Q3 2017 | 4 | $0.42 | $0.52 | $0.49 |
| Q4 2017 | 4 | $0.54 | $0.60 | $0.57 |
| Q1 2018 | 2 | $0.46 | $0.51 | $0.49 |
| Q2 2018 | 2 | $0.51 | $0.55 | $0.53 |
| Q3 2018 | 2 | $0.57 | $0.57 | $0.57 |
| Q4 2018 | 2 | $0.65 | $0.70 | $0.68 |
(Data provided by Zacks Investment Research)
Dividend History for Integra LifeSciences Holdings Corporation (NASDAQ:IART)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Integra LifeSciences Holdings Corporation (NASDAQ:IART)Insider Ownership Percentage: 21.40%
Institutional Ownership Percentage: 89.70%
Insider Trades by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/25/2017 | Stuart Essig | Director | Sell | 135,000 | $49.90 | $6,736,500.00 | |
| 5/23/2017 | Stuart Essig | Director | Sell | 140,000 | $48.01 | $6,721,400.00 | |
| 5/4/2017 | Glenn Coleman | VP | Sell | 13,865 | $45.91 | $636,542.15 | |
| 5/4/2017 | James M Sullivan | Director | Sell | 15,658 | $45.89 | $718,545.62 | |
| 11/8/2016 | Peter J Arduini | CEO | Sell | 24,009 | $79.51 | $1,908,955.59 | |
| 8/23/2016 | Raymond G Murphy | Director | Sell | 2,600 | $86.64 | $225,264.00 | |
| 8/9/2016 | Peter J Arduini | CEO | Sell | 24,009 | $84.52 | $2,029,240.68 | |
| 8/4/2016 | Raymond G Murphy | Director | Sell | 2,610 | $84.83 | $221,406.30 | |
| 8/1/2016 | Richard D Gorelick | VP | Sell | 4,000 | $84.60 | $338,400.00 | |
| 5/9/2016 | Joseph Vinhais | VP | Sell | 972 | $73.36 | $71,305.92 | |
| 5/4/2016 | Glenn Coleman | CFO | Sell | 3,563 | $70.62 | $251,619.06 | |
| 5/3/2016 | Christian S Schade | Director | Sell | 7,829 | $70.42 | $551,318.18 | |
| 5/2/2016 | Daniel L Reuvers | VP | Sell | 1,000 | $71.43 | $71,430.00 | |
| 4/29/2016 | Richard D Gorelick | VP | Sell | 4,000 | $70.72 | $282,880.00 | |
| 4/27/2016 | Stuart Essig | Director | Sell | 104,390 | $70.15 | $7,322,958.50 | |
| 4/6/2016 | Stuart Essig | Director | Sell | 21,100 | $66.19 | $1,396,609.00 | |
| 4/5/2016 | Stuart Essig | Director | Sell | 83,290 | $66.68 | $5,553,777.20 | |
| 4/4/2016 | Stuart Essig | Director | Sell | 42,150 | $67.26 | $2,835,009.00 | |
| 5/7/2015 | Stuart Essig | Director | Sell | 75,000 | $64.32 | $4,824,000.00 | |
| 5/6/2015 | Stuart Essig | Director | Sell | 125,000 | $64.83 | $8,103,750.00 | |
| 1/2/2015 | Judith Ogrady | VP | Sell | 3,500 | $53.33 | $186,655.00 | |
| 10/28/2014 | Stuart Essig | Director | Sell | 147,098 | $49.58 | $7,293,118.84 | |
| 10/27/2014 | Stuart Essig | Director | Sell | 41,268 | $49.56 | $2,045,242.08 | |
| 9/2/2014 | Judith Ogrady | VP | Sell | 2,500 | $49.82 | $124,550.00 | |
| 8/27/2014 | Richard D Gorelick | VP | Sell | 7,000 | $50.03 | $350,210.00 | |
| 8/25/2014 | John B Henneman III | CAO | Sell | 20,000 | $50.12 | $1,002,400.00 | |
| 8/22/2014 | Deborah A Leonetti | VP | Sell | 1,000 | $50.96 | $50,960.00 | |
| 8/8/2014 | Brian Larkin | VP | Sell | 1,947 | $48.28 | $94,001.16 | |
| 7/30/2014 | Stuart Essig | Director | Sell | 50,800 | $47.76 | $2,426,208.00 | |
| 7/23/2014 | Stuart Essig | Director | Sell | 27,819 | $47.80 | $1,329,748.20 | |
| 7/1/2014 | Judith Ogrady | VP | Sell | 2,500 | $47.54 | $118,850.00 | |
| 6/23/2014 | Stuart Essig | Director | Sell | 21,381 | $47.76 | $1,021,156.56 | |
| 4/3/2014 | Stuart Essig | Director | Sell | 6,344 | $46.01 | $291,887.44 | |
| 4/2/2014 | Stuart Essig | Director | Sell | 76,177 | $46.05 | $3,507,950.85 | |
| 3/31/2014 | Stuart Essig | Director | Sell | 17,479 | $46.05 | $804,907.95 | |
| 3/10/2014 | Deborah Leonetti | VP | Sell | 7,563 | $49.22 | $372,250.86 | |
| 3/4/2014 | Richard Gorelick | VP | Sell | 2,000 | $47.98 | $95,960.00 | |
| 2/28/2014 | Christian Schade | Director | Sell | 7,500 | $47.06 | $352,950.00 | |
| 2/27/2014 | Brian Larkin | VP | Sell | 3,265 | $46.15 | $150,679.75 | |
| 2/27/2014 | John Henneman III | CFO | Sell | 5,000 | $46.07 | $230,350.00 | |
| 1/16/2014 | Stuart Essig | Director | Sell | 8,037 | $49.59 | $398,554.83 | |
| 1/14/2014 | Stuart Essig | Director | Sell | 10,600 | $49.50 | $524,700.00 | |
| 1/13/2014 | Stuart Essig | Director | Sell | 99,032 | $49.51 | $4,903,074.32 | |
| 1/9/2014 | Stuart Essig | Director | Sell | 114,431 | $49.58 | $5,673,488.98 | |
| 8/30/2013 | Richard Gorelick | VP | Sell | 3,000 | $40.79 | $122,370.00 | |
| 8/23/2013 | Deborah Leonetti | VP | Sell | 8,906 | $41.68 | $371,202.08 | |
| 8/19/2013 | Brian Larkin | VP | Sell | 7,490 | $41.90 | $313,831.00 | |
| 8/19/2013 | John Henneman III | CFO | Sell | 30,000 | $42.08 | $1,262,400.00 | |
| 8/1/2013 | Judith Ogrady | VP | Sell | 1,000 | $39.50 | $39,500.00 | |
| 7/30/2013 | Judith Ogrady | VP | Sell | 2,000 | $38.50 | $77,000.00 | |
| 5/31/2013 | Jerry E Corbin | VP | Sell | 1,876 | $38.07 | $71,419.32 | |
(Data available from 1/1/2013 forward)
Headline Trends for Integra LifeSciences Holdings Corporation (NASDAQ:IART)
Latest Headlines for Integra LifeSciences Holdings Corporation (NASDAQ:IART)
| Source: |
|
| Date | Headline |
|---|
 | Analysts Expect Integra LifeSciences Holdings Corporation (NASDAQ:IART) Will Announce Quarterly Sales of $282.89 Million
www.americanbankingnews.com - July 21 at 5:22 PM |
| Contrasting Lombard Medical (EVAR) & Integra LifeSciences Holdings Corporation (IART)
www.americanbankingnews.com - July 19 at 4:12 PM |
| Zacks: Analysts Expect Integra LifeSciences Holdings Corporation (NASDAQ:IART) Will Announce Earnings of $0.44 Per Share
www.americanbankingnews.com - July 19 at 2:44 PM |
| Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 17 at 2:50 PM |
 | Integra LifeSciences to Host Its Second Quarter 2017 Earnings Results ...
www.nasdaq.com - July 12 at 4:26 AM |
 | Integra LifeSciences to Host Its Second Quarter 2017 Earnings Results Conference Call on July 26, 2017
finance.yahoo.com - July 11 at 11:25 PM |
| Cantor Fitzgerald Reiterates "Overweight" Rating for Integra LifeSciences Holdings Corporation (IART)
www.americanbankingnews.com - July 10 at 3:46 PM |
| Cantor Fitzgerald Comments on Integra LifeSciences Holdings Corporation's FY2017 Earnings (IART)
www.americanbankingnews.com - July 6 at 9:17 AM |
| Integra LifeSciences Holdings Corporation (IART) Earns Overweight Rating from Analysts at Cantor Fitzgerald
www.americanbankingnews.com - June 29 at 6:42 PM |
| Integra LifeSciences Holdings Corporation (IART) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - June 29 at 12:52 AM |
| Oppenheimer Holdings, Inc. Analysts Give Integra LifeSciences Holdings Corporation (IART) a $60.00 Price Target
www.americanbankingnews.com - June 25 at 11:06 PM |
| $282.89 Million in Sales Expected for Integra LifeSciences Holdings Corporation (IART) This Quarter
www.americanbankingnews.com - June 25 at 9:46 AM |
| Integra LifeSciences Holdings Corporation (IART) Expected to Post Earnings of $0.44 Per Share
www.americanbankingnews.com - June 23 at 11:27 AM |
| Integra LifeSciences Holdings Corporation (IART) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 20 at 3:04 PM |
 | Integra LifeSciences to Hold Second International Tissue Technologies Symposium on June 15 - 16, 2017 in Berlin, Germany
feeds.benzinga.com - June 15 at 4:25 AM |
| Endologix (ELGX) & Integra Lifesciences Holdings Corp (IART) Financial Analysis
www.americanbankingnews.com - June 10 at 7:54 AM |
| Integra's Massive Run-Up Expected to Continue as J&J's Surgical Business Joins the Fold
finance.yahoo.com - June 1 at 6:38 PM |
| FY2018 EPS Estimates for Integra Lifesciences Holdings Corp (IART) Lowered by Jefferies Group
www.americanbankingnews.com - June 1 at 12:50 PM |
| Integra Lifesciences Holdings Corp (IART) Expected to Announce Quarterly Sales of $282.89 Million
www.americanbankingnews.com - June 1 at 12:48 PM |
| Jefferies Group LLC Reaffirms Buy Rating for Integra Lifesciences Holdings Corp (IART)
www.americanbankingnews.com - May 31 at 1:16 PM |
 | Integra LifeSciences: Two Recent Acquisitions Set To Drive Substantial Upside
seekingalpha.com - May 30 at 10:42 PM |
| Integra Lifesciences Holdings Corp (IART) Expected to Announce Earnings of $0.44 Per Share
www.americanbankingnews.com - May 30 at 7:38 AM |
| Integra LifeSciences (IART) Up 8.5% Since Earnings Report: Can It Continue?
finance.yahoo.com - May 29 at 9:43 AM |
| Integra Lifesciences Holdings Corp (IART) Director Stuart Essig Sells 135,000 Shares
www.americanbankingnews.com - May 26 at 7:26 PM |
| Integra Lifesciences Holdings Corp (IART) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 26 at 2:53 PM |
| Integra Lifesciences Holdings Corp (IART) Director Sells $6,721,400.00 in Stock
www.americanbankingnews.com - May 24 at 7:21 PM |
| Integra LifeSciences to Offer aap's LOQTEQ System in the US
www.nasdaq.com - May 24 at 5:40 PM |
| Integra LifeSciences to Present at Healthcare Conferences in June 2017
finance.yahoo.com - May 24 at 5:40 PM |
| ValuEngine Lowers Integra Lifesciences Holdings Corp (IART) to Hold
www.americanbankingnews.com - May 23 at 5:04 PM |
 | BRIEF-Integra Lifesciences Holdings Corp signs an agreement with AAP Implantate AG
www.reuters.com - May 23 at 11:24 AM |
| Integra LifeSciences Announces Agreement with aap to Distribute LOQTEQ® Distal Radius System
finance.yahoo.com - May 23 at 11:24 AM |
| Integra LifeSciences Announces the European Launch of Integra® Dermal Regeneration Template Single Layer "Thin"
finance.yahoo.com - May 17 at 10:04 AM |
| Integra Lifesciences Holdings Corp (IART) Given a $54.00 Price Target by Oppenheimer Holdings Inc. Analysts
www.americanbankingnews.com - May 15 at 2:34 PM |
| Integra LifeSciences launches SurgiMend® MP Collagen Matrix for Hernia Repair
finance.yahoo.com - May 12 at 6:30 PM |
| ETFs with exposure to Integra LifeSciences Holdings Corp. : May 11, 2017
finance.yahoo.com - May 11 at 6:23 PM |
| Analysts Anticipate Integra Lifesciences Holdings Corp (IART) Will Post Quarterly Sales of $282.89 Million
www.americanbankingnews.com - May 6 at 8:47 AM |
| Insider Selling: Integra Lifesciences Holdings Corp (IART) Director Sells 15,658 Shares of Stock
www.americanbankingnews.com - May 5 at 8:11 PM |
| Integra Lifesciences Holdings Corp (IART) VP Sells $636,542.15 in Stock
www.americanbankingnews.com - May 5 at 8:11 PM |
| Analysts Anticipate Integra Lifesciences Holdings Corp (IART) to Post $0.44 Earnings Per Share
www.americanbankingnews.com - May 4 at 1:24 PM |
| Integra LifeSciences to Present at Healthcare Conferences in May 2017
finance.yahoo.com - May 3 at 5:26 PM |
| Positive Media Coverage Very Likely to Impact Integra Lifesciences Holdings Corp (IART) Stock Price
www.americanbankingnews.com - May 2 at 6:10 PM |
| Integra Lifesciences Holdings Corp (IART) Given New $48.00 Price Target at Royal Bank of Canada
www.americanbankingnews.com - May 2 at 7:54 AM |
| Integra Lifesciences Holdings Corp (IART) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 1 at 6:38 PM |
| Jefferies Group Comments on Integra Lifesciences Holdings Corp's Q4 2017 Earnings (IART)
www.americanbankingnews.com - May 1 at 11:34 AM |
| Q2 2017 EPS Estimates for Integra Lifesciences Holdings Corp Raised by Northcoast Research (IART)
www.americanbankingnews.com - May 1 at 8:11 AM |
| Favorable Press Coverage Likely to Impact Integra Lifesciences Holdings Corp (IART) Stock Price
www.americanbankingnews.com - April 29 at 8:50 PM |
| Integra Lifesciences Holdings Corp (IART) Given Buy Rating at Jefferies Group LLC
www.americanbankingnews.com - April 29 at 1:05 AM |
| Integra LifeSciences Holdings Corp. :IART-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017
finance.yahoo.com - April 28 at 6:46 PM |
| Jefferies Group Analysts Raise Earnings Estimates for Integra Lifesciences Holdings Corp (IART)
www.americanbankingnews.com - April 28 at 1:25 PM |
| Integra Lifesciences Holdings Corp (IART) Forecasted to Post Q2 2017 Earnings of $0.44 Per Share
www.americanbankingnews.com - April 28 at 7:54 AM |
Integra LifeSciences Holdings Corporation (IART) Chart for Sunday, July, 23, 2017
